Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cagrilintide Thorough QT Study
NCT05804162Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Apr 2023
- Primary completion
- Aug 2023
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of cagrilintide in obesity (3 arms), sponsored by Novo Nordisk. Primary endpoint: Change From Baseline in Fridericia Heart Rate Corrected QT Interval (QTcF) at 72 hours. Started Apr 2023; status: completed.
02
Drugs
cagrilintide
03
Conditions
obesity
Beyond the preview
Go deeper on NCT05804162.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05804162.